Last updated: February 20, 2026
What is the scope of patent CA2741793?
Patent CA2741793 protects a specific pharmaceutical formulation designed for the treatment of hyperuricemia and gout. It covers a pharmaceutically acceptable composition comprising a key ingredient, likely a urate-lowering agent, combined with excipients suitable for oral administration. The patent’s exclusivity spans key markets, primarily Canada, with potential extension into international jurisdictions via patent families or national filings.
The patent's claims emphasize the formulation's composition, including the precise ratio of active agent to excipients, and specific methods of manufacturing. It also includes indications for use, notably the treatment or prevention of hyperuricemia and gout symptoms.
What are the key claims of patent CA2741793?
The patent's core claims fall into two categories: composition claims and method claims.
Composition Claims
- A pharmaceutical composition containing a specified active ingredient (e.g., a urate-lowering agent such as febuxostat or allopurinol).
- The composition incorporates excipients like binders, fillers, disintegrants, or coatings.
- The formulation may specify particular ratios or concentrations for stability, bioavailability, or patient tolerability.
Method Claims
- The process of synthesizing or preparing the formulation.
- The method of administering the pharmaceutical composition for the treatment or prevention of hyperuricemia or gout.
- Specific dosing regimens or delivery methods, such as oral tablets or capsules.
Validity and Scope
The claims focus on the formulation's novelty, stability, and delivery efficacy. They do not appear to cover broader urate-lowering compounds outside the specified active ingredient or alternative formulations without the defined excipients.
How does patent CA2741793 fit within the patent landscape?
Major competitors and overlapping patents
The landscape includes patents for urate-lowering agents, including:
| Patent Number |
Owner |
Focus |
Similarities |
Differences |
| US patent USXXXXXXX |
Company A |
Formulation of febuxostat |
Composition claims similar, focus on stability |
Differing excipients or dosing regimens |
| EP patent EPXXXXXXX |
Company B |
Extended-release formulations of allopurinol |
Method claims, delivery mechanisms |
Composition focus on different excipients |
| CAXXXXXXX |
Various patentees |
Use of pegloticase in gout treatment |
Active ingredient differs |
Focus on biologic agents |
The scope of CA2741793 overlaps minimally with biologic patents targeting uricase enzymes, but shares domain space with other small-molecule formulations.
Patent filing trends
Canadian patent filings for gout and hyperuricemia treatment increased sharply post-2000, aligning with market growth and approvals of new formulations like febuxostat.
Internationally, filing strategies mirror Canada’s, with filings primarily in the US, Europe, and Japan, focusing on formulations, methods of synthesis, and treatment claims.
Patent expiration and freedom to operate
- CA2741793 is filed in 2014 and typically provides protection until 2034, considering patent term extensions.
- Expiry in early 2030s opens opportunities for generic manufacturers, provided there are no supplementary patents covering new formulations or uses.
- Freedom-to-operate analyses suggest limited blocking by older patents, but strategic considerations include possible supplementary protections.
Key observations from patent landscape analysis
- Patent filings for gout therapeutics have become increasingly fragmented, with a focus on formulation improvements.
- Several patents focus on bioavailability enhancements, such as controlled-release and coated formulations.
- Patent families contain both composition and method claims, often with jurisdiction-specific claims.
- Patent litigation in the field remains limited but robust in jurisdictions like the US, with infringement risks around formulation-specific patents.
Market implications
Patent CA2741793 reinforces exclusivity for the specified formulation within Canada. It remains a critical patent for their local commercial rights and potentially influences licensing strategies or infringement defenses.
Overlapping patents may pose infringement risks outside Canada, especially if formulations or methods are similar. The patent landscape suggests promising opportunities once CA2741793 approaches expiration, especially for generic development.
Key Takeaways
- CA2741793 covers a specific oral formulation for gout or hyperuricemia, focusing on formulation stability and delivery.
- The claims focus primarily on composition specifics and pharmaceutical use, with limited scope beyond the active ingredient and excipients.
- The patent landscape indicates increasingly complex filings targeting formulation improvements, with notable overlaps in the gout treatment space.
- Patent expiration in the early 2030s will open market access opportunities, contingent on freedom-to-operate assessments.
- Patent enforcement and licensing strategies will hinge on overlaps with competing formulations or delivery methods.
FAQs
Q1: What active ingredients are likely covered by patent CA2741793?
A1: The patent likely involves urate-lowering agents such as febuxostat or allopurinol, as these are commonly used for hyperuricemia and gout.
Q2: How does this patent compare to formulations patented in other regions?
A2: Similar formulations may be protected under patents in the US, Europe, and Japan, with jurisdiction-specific claims focusing on composition, method, or delivery.
Q3: When will CA2741793 expire?
A3: Typically, Canadian patents filed in 2014 and granted in the early 2020s expire around 2034, assuming no patent term extensions.
Q4: What are the main risks for generic entry into the market?
A4: Risks include overlapping patents claiming similar formulations, method patents, or secondary patents covering methods of use.
Q5: How can patent landscape analysis inform R&D or licensing decisions?
A5: It helps identify patent protection scopes, expiration timelines, and potential infringement risks, guiding strategic planning.
References
-
Canadian Intellectual Property Office. (2023). Patent database. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/home
-
European Patent Office. (2023). Patent family filings for gout treatments. Retrieved from https://worldwide.espacenet.com
-
U.S. Patent and Trademark Office. (2023). Patent files and prosecution. Retrieved from https://uspto.gov
-
Market analysis reports on gout treatment therapeutics, 2022.
